title: [Clinical usefulness of positron emission tomography in prostate cancer].
abstract: In prostate cancer, use of FDG, the radiopharmaceutical currently most widely used in oncology, is limited to the most aggressive cancers and, in the absence of another tracer, to attempting to localise occult recurrences detected biochemically (elevated PSA serum levels). Four other PET tracers are currently suggested in various situations of prostate cancer development: for guiding biopsies, for diagnosis and staging of the primary cancer and of local or metastatic recurrences, especially in bone, and for localizing occult biochemical recurrence. This article is illustrated by cases summarising our experience with fluoromethylcholine-(18F) and PET/CT. They cover a wide spectrum of clinical settings: localisation of intraprostatic neoplastic lesions, initial staging, monitoring treatment by ultrasound, detection of occult recurrences and characterisation of images on conventional imaging modalities, which are questionable or difficult to interpret.
authors.affiliation: Service de médecine nucléaire, Hôpital Tenon, Université Pierre et Marie Curie, Paris. jean-noel.talbot@tnn.aphp.fr
authors.forename: Jean-Noël
authors.initials: JN
authors.lastname: Talbot
authors.forename: Fabrice
authors.initials: F
authors.lastname: Gutman
authors.forename: Virginie
authors.initials: V
authors.lastname: Huchet
authors.forename: Khaldoun
authors.initials: K
authors.lastname: Kerrou
authors.forename: Sona
authors.initials: S
authors.lastname: Balogova
authors.forename: Nacer
authors.initials: N
authors.lastname: Kerrouche
authors.forename: Françoise
authors.initials: F
authors.lastname: Montravers
authors.forename: Dany
authors.initials: D
authors.lastname: Grahek
authors.forename: Olivier
authors.initials: O
authors.lastname: Cussenot
authors.forename: Bernard
authors.initials: B
authors.lastname: Gattegno
authors.forename: Philippe
authors.initials: P
authors.lastname: Thibault
mesh_terms: D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary; D002794:Choline / Q000031:analogs & derivatives; D005462:Fluorine Radioisotopes; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology; D019275:Radiopharmaceuticals
chemical_list: D005462:Fluorine Radioisotopes; D019275:Radiopharmaceuticals; C516370:fluoromethylcholine; D019788:Fluorodeoxyglucose F18; D002794:Choline